Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair

Science Translational Medicine

Volumn 7, Issue 312, 2015, Pages

  Tarish, Firas L ^a,b   Schultz, Niklas ^a   Tanoglidi, Anna ^c   Hamberg, Hans ^b   Letocha, Henry ^b   Karaszi, Katalin ^d   Hamdy, Freddie C ^d   Granfors, Torvald ^b   Helleday, Thomas ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; KU ANTIGEN; LEUPRORELIN; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA LIGASE; H2AFX PROTEIN, HUMAN; HISTONE; NHEJ1 PROTEIN, HUMAN; RADIOSENSITIZING AGENT;

ARTICLE; CANCER RADIOTHERAPY; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION RESPONSE; RADIOSENSITIZATION; UPREGULATION; ADULT; AGED; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; ORCHIECTOMY; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTORS, ANDROGEN; YOUNG ADULT;

EID: 84946775645     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac5671     Document Type: Article

References (29)

1. A. Pollack, G. K. Zagars, External beam radiotherapy dose response of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 39, 1011-1018 (1997).
2. A. L. Zietman, J. J. Coen, K. C. Dallow, W. U. Shipley, The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 32, 287-292 (1995).
3. R. Valicenti, J. Lu, M. Pilepich, S. Asbell, D. Grignon, Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J. Clin. Oncol. 18, 2740-2746 (2000).
4. M. Roach III, J. Lu, M. V. Pilepich, S. O. Asbell, M. Mohiuddin, R. Terry, D. Grignon, Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J. Urol. 161, 864-868 (1999).
5. P. Milecki, P. Martenka, A. Antczak, Z. Kwias, Radiotherapy combined with hormonal therapy in prostate cancer: The state of the art. Cancer Manag. Res. 2, 243-253 (2010).
6. A. R. Gottschalk, M. Roach III, The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br. J. Cancer 90, 950-954 (2004).
7. M. V. Pilepich, K. Winter, M. J. John, J. B. Mesic, W. Sause, P. Rubin, C Lawton, M. Machtay, D. Grignon, Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252 (2001).
8. A. V. D'Amico, M. H. Chen, A. A. Renshaw, M. Loffredo, P. W. Kantoff, Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299, 289-295 (2008).
9. M. Bolla, G. Van Tienhoven, P. Warde, J. B. Dubois, R. O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, I. Billiet, J. L. Torecilla, R. Pfeffer, C L. Cutajar, T. Van der Kwast, L. Collette, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11, 1066-1073 (2010).
10. G. K. Zagars, A. Pollack, L. G. Smith, Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 44, 809-819 (1999).
11. A. Dal Pra, F. L. Cury, L. Souhami, Combining radiation therapy and androgen deprivation for localized prostate cancer - A critical review. Curr. Oncol. 17, 28-38 (2010).
12. T. Helleday, J. Lo, D. C. van Gent, B. P. Engelward, DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair 6, 923-935 (2007).
13. A. A. Goodarzi, P. A. Jeggo, The repair and signaling responses to DNA double-strand breaks. Adv. Genet. 82, 1-45 (2013).
14. P. Ahnesorg, P. Smith, S. P. Jackson, XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 124, 301-313 (2006).
15. P. A. Jeggo, Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat. Res. 150, S80-S91 (1998).
16. F. L. Al-Ubaidi, N. Schultz, O. Loseva, L. Egevad, T. Granfors, T. Helleday, Castration therapy results in decreased Ku70 levels in prostate cancer. Clin. Cancer Res. 19, 1547-1556 (2013).
17. W. R. Polkinghorn, J.S. Parker, M.X. Lee, E. M. Kass, D. E. Spratt, P.J. Iaquinta, V. K. Arora, W.-F. Yen, LCai, D. Zheng, B. S. Carver, Y. Chen, P.A. Watson, N.P. Shah, S. Fujisawa, A G. Goglia, A. Gopalan, H. Hieronymus, J. Wongvipat, P.T. Scardino, M.J. Zelefsky, M. Jasin, J. Chaudhuri, S. N. Powell, C. L. Sawyers, Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3, 1245-1253 (2013).
18. J. F. Goodwin, M. J. Schiewer, J. L. Dean, R. S. Schrecengost, R. de Leeuw, S. Han, T. Ma, R. B. Den, A. P. Dicker, F. Y. Feng, K. E. Knudsen, A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 3, 1254-1271 (2013).
19. A. Sak, M. Stuschke, Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin. Radiat. Oncol. 20, 223-231 (2010).
20. K. Meek, P. Douglas, X. Cui, Q. Ding, S. P. Lees-Miller, Trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Mol. Cell. Biol. 27, 3881-3890 (2007).
21. M. Takata, M. S. Sasaki, E. Sonoda, C. Morrison, M. Hashimoto, H. Utsumi, Y. Yamaguchi-Iwai, A. Shinohara, S. Takeda, Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 17, 5497-5508 (1998).
22. K. Valerie, L. F. Povirk, Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22, 5792-5812 (2003).
23. A. Kakarougkas, P. A. Jeggo, DNA DSB repair pathway choice: An orchestrated handover mechanism. Br. J. Radiol. 87, 20130685 (2014).
24. G. L. Mayeur, W.-J. Kung, A. Martinez, C. Izumiya, D. J. Chen, H.-J. Kung, Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J. Biol. Chem. 280, 10827-10833 (2005).
25. K. Fizazi, H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi, R. J. Jones, J. N. Staffurth, S. North, N.J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. B. Goodman Jr., C.N. Sternberg, J. Hui Li, T. Kheoh, C M. Haqq, J. S. de Bono; COU-AA-301 Investigators, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983-992 (2012).
26. H. I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C. N. Sternberg, K. Miller, R. de Wit, P. Mulders, K. N. Chi, N. D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J. S. de Bono; AFFIRM Investigators, Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
27. E. A. Mostaghel, S. T. Page, D. W. Lin, L. Fazli, I. M. Coleman, L. D. True, B. Knudsen, D. L. Hess, C. C. Nelson, A. M. Matsumoto, W. J. Bremner, M. E. Gleave, P. S. Nelson, Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67, 5033-5041 (2007).
28. D. G. Bostwick, Grading prostate cancer. Am. J. Clin. Pathol. 102, S38-S56 (1994).
29. C. A. Schneider, W. S. Rasband, K. W. Eliceiri, NIH Image to ImageJ: 25 Years of image analysis. Nat. Methods 9, 671-675 (2012).